2026-02-19
Spermidine and Autophagy: Human Evidence, Protocol Context, and Unknowns
Spermidine has strong mechanistic and observational support, but randomized human outcome evidence remains limited and ongoing.
2026-02-18
POLYCAD Trial: Spermidine Supplementation in Coronary Artery Disease — Design and Interim Context
The POLYCAD trial is testing 24 mg/day spermidine in 187 older adults with coronary artery disease for 48 weeks. Trial completion is expected August 2026 — no efficacy results exist yet. Prior cohort data from Eisenberg et al. 2016 provides the rationale.
2026-02-17
Caloric Restriction Mimetics in 2025: Multi-Pathway Geroprotectors Under Clinical Evaluation
A 2025 Biogerontology review maps geroprotective compounds targeting AMPK, mTOR, and autophagy pathways. Most remain at biomarker endpoints; hard longevity data in humans is largely absent.
2026-02-13
Alpha-Ketoglutarate and Aging: TET Enzyme Activity, Epigenetic Clocks, and Ca-AKG Trials
Alpha-ketoglutarate (AKG) is a TCA cycle intermediate that activates TET enzymes involved in DNA demethylation. The TRIIM-X trial using Ca-AKG reported a reduction in biological age markers. Evidence is preliminary but mechanistically credible.
2026-02-09
Calcium Alpha-Ketoglutarate and Epigenetic Aging: Biological Age Reduction Evidence
Calcium alpha-ketoglutarate (Ca-AKG) is an intermediate in the Krebs cycle and an alpha-ketoglutarate-dependent dioxygenase co-factor critical for epigenetic regulation. A clinical trial showed an 8-year reduction in biological age by DNA methylation clock. Evidence is early but striking.